乳腺癌耐药蛋白在癌组织中的表达及临床意义  

The expression of breast cancer resistance protein(BCRP) in primary breast carcinoma and its clinical impact

作　　者：王蓓[1] 徐熙善[1] 骆健生[1] 洪中武[1] 王朝明[1] 李曙光[1] 丁丰盛[1] 

机构地区：[1]金华市中心医院肿瘤科,浙江金华321000

出　　处：《中国癌症杂志》2006年第1期58-60,共3页China Oncology

摘　　要：背景与目的:乳腺癌耐药蛋白(BCRP)是新发现的多药耐药相关的膜转运蛋白,了解耐药蛋白在乳腺癌组织中的表达,对乳腺癌患者的治疗是有重要意义。我们研究了BCRP在乳腺癌组织中的表达以及它在乳腺癌化疗指导中的潜在意义,评估其在判断乳腺癌化疗敏感性中的作用。方法:应用流式细胞术检测31例原发乳腺癌组织中BCRP的表达,并分析其与临床病理特征的关系及对预后的影响。结果:BCRP在乳腺癌组织中的表达(0.282581±0.183686)与正常对照组(0.03125±1.000905)比较差别有非常显著性(P<0.01)。乳腺癌组织BCRP与ER、PR、c-erb-B-2、EGFR阴阳性值均数的比较,以及腋淋巴结无转移、腋淋巴结转移组之间BCRP表达值差均无显著性。结论:BCRP在乳腺癌组织中具有一定的表达水平,是独立于ER、PR、c-erb-B-2、EGFR的细胞膜蛋白。BCRP高表达者采用表阿霉素为辅的联合化疗可取得满意结果。Background and purpose： BCRP was recently discoveried as a membrane transport protein affiliated with multiple drug resistance（ MDR）. The aim of present study was to investigate the expression of breast cancer resistance protein（BCRP） in primary breast carcinoma and its potential significance of guiding breast carcinoma chemotherapy and to determine whether such expression can be used as a predict factor for chemosensitivity. Methods： Expression of BCRP in 31 primary breast carcinoma tissues was determined by flow cytometry. The relationship between the expression of BCRP with the cliniepathological characteristics and the prognosis of breast carcinoma patients was also analyzed. Results： The expression level of BCRP was higher in breast carcinoma tissue（0. 282581± 0. 183686） than control group（0. 03125 ± 1. 000905）. There was no statistical difference befween BCRP and state of ER, PR, C-erbB2 and EGFR in breast carcinoma tissues. In addition, it was the same situation no matter whether axillary lymph node was metastatasied or not. Conclusions： The results suggest that BCRP is expressed in primary breast carcinoma and is a cell membrane protein independent on ER, PR, c-erb-B-2, EGFR. Based chemotherapy is more effective for the patients with the overexpression of BCRP in primary breast carcinoma tissue.

关 键 词：乳腺癌耐药蛋白 乳腺癌 化疗 流式细胞术 

分 类 号：R737.9[医药卫生—肿瘤]